Inventiva (DB:6IV) - Hisse Senedi Fiyatı, Haberler ve Analizler

6IV Stoklara Genel Bakış

6IV temel anali̇z
Kar Tanesi Skoru
Değerleme	0/6
Gelecekteki Büyüme	3/6
Geçmiş Performans	0/6
Finansal Sağlık	2/6
Temettüler	0/6

Ödüller

Gelirin yılda 47.46% oranında artması öngörülüyor

Risk Analizi

Son 3 ayda hisse senedi fiyatı oldukça dalgalıydı

Negatif hissedar öz sermayesi

Hissedarlar geçen yıl önemli ölçüde sulandırıldı

Şu anda kârlı değil ve önümüzdeki 3 yıl içinde kârlı hale gelmesi beklenmiyor

Inventiva S.A. Rakipler

Heidelberg Pharma

XTRA:HPHA

€111.9m

Formycon

XTRA:FYB

€882.0m

2invest

XTRA:2INV

€64.4m

Biotest

XTRA:BIO3

€1.3b

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Inventiva
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	€2.42
52 Haftanın En Yüksek Seviyesi	€4.21
52 Haftanın En Düşük Seviyesi	€1.45
Beta	0.80
11 Aylık Değişim	-4.35%
3 Aylık Değişim	12.56%
1 Yıllık Değişim	-35.55%
33 Yıllık Değişim	-79.49%
5 Yıllık Değişim	n/a
Halka arzdan bu yana değişim	-79.53%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	6IV	DE Biotechs	DE Pazar
7D	0.8%	1.2%	1.0%
1Y	-35.6%	-19.2%	7.7%

Getiri vs. Endüstri: 6IV geçen yıl % -19.2 oranında getiri sağlayan German Biotechs sektörünün gerisinde kaldı.

Getiri vs Piyasa: 6IV geçen yıl % 7.7 oranında getiri sağlayan German Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is 6IV's price volatile compared to industry and market?
6IV volatility
6IV Average Weekly Movement	15.3%
Biotechs Industry Average Movement	6.7%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	11.4%
10% least volatile stocks in DE Market	2.4%

İstikrarlı Hisse Senedi Fiyatı: 6IV hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: 6IV 'nin haftalık oynaklığı ( 15% ) geçen yıl boyunca sabit kaldı, ancak hala German hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2011	123	Frederic Cren	www.inventivapharma.com

Klinik aşamada bir biyofarmasötik şirketi olan Inventiva S.A., alkolik olmayan steatohepatit (NASH) ve diğer hastalıkların tedavisi için oral küçük moleküllü tedavilerin geliştirilmesine odaklanmaktadır. Lider ürün adayı, NASH tedavisi için Faz III klinik çalışmasında olan Lanifibranor'dur. Şirket ayrıca mukopolisakkaridoz tip VI hastalarının tedavisi için Odiparcil'i geliştirmektedir.

Inventiva S.A. Temel Bilgiler Özeti

Inventiva'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
6IV temel i̇stati̇sti̇kler
Piyasa değeri	€206.37m
Kazançlar(TTM)	-€104.19m
Gelir(TTM)	€19.28m

10.7x

P/S Oranı

-2.0x

F/K Oranı

6IV aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
6IV gelir tablosu (TTM)
Gelir	€19.28m
Gelir Maliyeti	€1.08m
Brüt Kâr	€18.19m
Diğer Giderler	€122.38m
Kazançlar	-€104.19m

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

Mar 26, 2025

Hisse başına kazanç (EPS)	-1.20
Brüt Marj	94.38%
Net Kâr Marjı	-540.52%
Borç/Özkaynak Oranı	-85.6%

6IV uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

6IV Stoklara Genel Bakış

Ödüller

Risk Analizi

Inventiva S.A. Rakipler

XTRA:HPHA

€111.9m

XTRA:FYB

€882.0m

XTRA:2INV

€64.4m

XTRA:BIO3

€1.3b

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Inventiva to Present Data from the Final Analysis of the Phase 2 Study Evaluating the Combination of Lanifibranor with Empagliflozin in Patients with Mash and T2d At the Aasld the Liver Meeting® Late-Breaker Session

Inventiva Announces the Positive Recommendation of the Fifth DMC of the Nativ3 Phase 3 Clinical Trial with Lanifibranor in Patients with Mash

New major risk - Shareholder dilution

Inventiva S.A. announced that it expects to receive €348 million in funding from a group of investors

First half 2024 earnings released: €0.94 loss per share (vs €1.32 loss in 1H 2023)

Inventiva Announces the Publication in Nature Communications of Additional Results from Native Phase IIb Clinical Trial Demonstrating Improvement of Markers of Cardiometabolic Health in Patients with MASH/NASH Treated with Lanifibranor

Recent updates

Inventiva to Present Data from the Final Analysis of the Phase 2 Study Evaluating the Combination of Lanifibranor with Empagliflozin in Patients with Mash and T2d At the Aasld the Liver Meeting® Late-Breaker Session

Inventiva Announces the Positive Recommendation of the Fifth DMC of the Nativ3 Phase 3 Clinical Trial with Lanifibranor in Patients with Mash

New major risk - Shareholder dilution

Inventiva S.A. announced that it expects to receive €348 million in funding from a group of investors

First half 2024 earnings released: €0.94 loss per share (vs €1.32 loss in 1H 2023)

Inventiva Announces the Publication in Nature Communications of Additional Results from Native Phase IIb Clinical Trial Demonstrating Improvement of Markers of Cardiometabolic Health in Patients with MASH/NASH Treated with Lanifibranor

Full year 2023 earnings released: €2.44 loss per share (vs €1.31 loss in FY 2022)

New minor risk - Share price stability

Inventiva S.A. Provides Update on its Clinical Trial NATiV3

Forecast to breakeven in 2026

Inventiva S.A. to Report First Half, 2024 Results on Sep 25, 2024

Inventiva Announces the Randomization of the First Patient in China in the NATiV3 Clinical Trial and Provides an Update on Its Clinical Development Program

First half 2023 earnings released: €1.32 loss per share (vs €0.72 loss in 1H 2022)

New major risk - Negative shareholders equity

New major risk - Financial position

Inventiva S.A. to Report Fiscal Year 2023 Results on Mar 27, 2024

Inventiva S.A. to Report Nine Months, 2023 Results on Sep 28, 2023

New major risk - Revenue and earnings growth

Inventiva Announces Positive Topline Results from the Investigator-Initiated Phase Ii Clinical Trial Evaluating Lanifibranor in Patients with T2d and NAFLD

Full year 2022 earnings released: €1.31 loss per share (vs €1.27 loss in FY 2021)

Forecast to breakeven in 2025

Inventiva S.A. to Report Fiscal Year 2022 Results on Mar 29, 2023

Inventiva S.A. Announces Changes to the Clinical Development of Lanifibranor, Including Plans for New Phase III Trial in Patients with NASH and Compensated Cirrhosis

Inventiva S.A. Announces Changes to the Clinical Development of Lanifibranor, Including Plans for New Phase III Trial in Patients with NASH and Compensated Cirrhosis

Inventiva S.A., Annual General Meeting, Jan 25, 2023

Inventiva Announces Lucy Lu as the Director of its Board of Directors

Insufficient new directors

Inventiva Provides Update on Development of cedirogant by AbbVie

First half 2022 earnings released: €0.72 loss per share (vs €0.60 loss in 1H 2021)

Inventiva S.A. to Report First Half, 2022 Results on Sep 21, 2022

Inventiva Announces the Screening of the First Patient in LEGEND , Phase IIa Combination Trial with Lanifibranor and Empagliflozin in Patients with NASH and T2D

Inventiva Announces Three Scientific Presentations At the EASL International Liver Congress™ 2022

Insufficient new directors

No longer forecast to breakeven

Inventiva S.A., Annual General Meeting, May 19, 2022

Inventiva S.A. Announces IND Application for the Phase Ii Combination Trial with Lanifibranor and Empagliflozin in Patients with Nash

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Forecast to breakeven in 2024

Inventiva S.A. to Report Fiscal Year 2021 Results on Mar 07, 2022

Inventiva receives a €4 Million Milestone Payment from AbbVie for Cedirogant Phase IIb Initiation

Forecast to breakeven in 2024

Inventiva Announces Positive Results of Clinical Thorough QT Study Conducted with Lanifibranor

Inventiva S.A. has completed a Follow-on Equity Offering in the amount of $30.00001 million.

Second quarter 2021 earnings released: €0.37 loss per share (vs €0.29 loss in 2Q 2020)

Inventiva Announces the Initiation of Its Pivotal Phase III Clinical trial Evaluating Lanifibranor in NASH

First quarter 2021 earnings released: €0.23 loss per share (vs €0.23 loss in 1Q 2020)

Full year 2020 earnings released: €0.99 loss per share (vs €1.29 loss in FY 2019)

Inventiva Announces Collaboration on Non-Invasive Biomarkers to Identify Patients Responding to Lanifibranor with Regards to Nash Resolution and Fibrosis Improvement

Inventiva S.A. to Report First Half, 2021 Results on Sep 20, 2021

New 90-day high: €12.92

Inventiva Announces Design of Phase III Clinical Trial with Lanifibranor in NASH

Inventiva Announces the Publication in the Journal of Hepatology of New Pre-Clinical Data Showing the Beneficial Effects of Lanifibranor on Cirrhosis

Inventiva S.A. Receives Positive Fda Feedback to Advance Its Lead Drug Candidate Lanifibranor into Pivotal Phase Iii in Nash

Inventiva Announces Appointment of Michael Cooreman as Chief Medical Officer

Inventiva Receives Fda Fast Track Designation in Mps Vi for Its Clinical-Stage Asset Odiparci

Inventiva Receives FDA Breakthrough Therapy Designation for Lead Drug Candidate Lanifibranor in NASH

New 90-day high: €11.34

Inventiva S.A. to Present the Results of Its Native Phase IIb Clinical Trial with Lanifibranor in Nash During Plenary Session at the Liver Meeting Digital Experience™ 2020

First half earnings released